{"classes":[{"categories":[{"measurements":[{"comment":"Median, lower and upper limit of 95% CI was not estimable for 1 participant.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, lower and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG002","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median, lower and upper limit of 95% CI was not estimable for 1 participant.","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due to low number of participants with events.","groupId":"OG004","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG005","lowerLimit":"1.94","upperLimit":"NA","value":"NA"},{"groupId":"OG006","lowerLimit":"3.13","upperLimit":"5.53","value":"3.93"},{"comment":"Median and upper limit of 95% CI was not estimable due to low number of participants with events.","groupId":"OG007","lowerLimit":"7.37","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"31"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"12"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"8"},{"groupId":"OG008","value":"0"}],"units":"Participants"}],"description":"DOR is defined as the time from the first overall response contributing to an objective response (CR or PR) to the earlier of the participant's death and first overall response of PD. CR was defined as disappearance of all target lesions. PR was defined as At least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters. PD was defined as at least a 20% increase in the SOD of target lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with Colorectal Cancer received epacadostat 100 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG000","title":"Phase 2: Epacadostat 100 mg + Nivolumab 240 in Colorectal Cancer"},{"description":"Participants with DLBCL received epacadostat 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG001","title":"Phase 2: Epacadostat 300 mg + Nivolumab 240 mg in DLBCL"},{"description":"Participants with Melanoma(I/O Naive) received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG002","title":"Phase 2: Epacadostat 100/300 mg + Nivolumab 240 mg in Melanoma(I/O Naive)"},{"description":"Participants with Melanoma (I/O Relapsed) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG003","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Relapsed)"},{"description":"Participants with Melanoma (I/O Refractory) received epacadostat 100 mg BID in combination with nivolumab 480 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG004","title":"Phase 2 Epacadostat 100mg + Nivolumab 480 mg in Melanoma (I/O Refractory)"},{"description":"Participants with NSCLC received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG005","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in NSCLC"},{"description":"Participants with Ovarian Cancer received epacadostat 100 mg or 300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG006","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Ovarian Cancer"},{"description":"Participants with SCCHN received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG007","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in SCCHN"},{"description":"Participants with Glioblastoma received epacadostat 100/300 mg BID in combination with nivolumab 240 mg IV infusion Q2W on Days 1, 15, 29, and 43 of each 8-week cycle.","id":"OG008","title":"Phase 2 Epacadostat 100/300 mg + Nivolumab 240 mg in Glioblastoma"}],"paramType":"MEDIAN","populationDescription":"The Phase 2 Full Analysis Population includes all participants enrolled in the study who received at least 1 dose of study drug. The data is reported only for responders and per cancer type for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From first dose up end of the study (up to approximately 6 years)","title":"Phase 2: Duration of Response","type":"SECONDARY","unitOfMeasure":"months"}